港股异动 | 科笛-B(02487)午后涨超30% CU-30101上市申请获受理 CU-10201临床试验结果近日发表

智通财经网07-31

智通财经APP获悉，科笛-B(02487)午后涨超30%，截至发稿，涨30.26%，报10.16港元，成交额5270.85万港元。消息面上，科笛发布公告，集团的CU-30101药品上市许可申请获得中国国家药品监督管理局受理。据悉，CU-30101是一种用于皮肤表皮手术的局部利多卡因丁卡因复合表皮麻醉乳膏剂。此外，科笛公布，其治疗非结节性中度至重度寻常痤疮产品CU-10201(外用4%米诺环素泡沫剂...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2455607971?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20240731/20240731151225_54433.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2024-07-31 15:11","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2455607971","market":"hk","top_or_hot":-1,"title":"港股异动 | 科笛-B(02487)午后涨超30% CU-30101上市申请获受理 CU-10201临床试验结果近日发表","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，科笛-B(02487)午后涨超30%，截至发稿，涨30.26%，报10.16港元，成交额5270.85万港元。消息面上，科笛发布公告，集团的CU-30101药品上市许可申请获得中国国家药品监督管理局受理。据悉，CU-30101是一种用于皮肤表皮手术的局部利多卡因丁卡因复合表皮麻醉乳膏剂。此外，科笛公布，其治疗非结节性中度至重度寻常痤疮产品CU-10201(外用4%米诺环素泡沫剂...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1157895.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科笛-B(02487)午后涨超30% CU-30101上市申请获受理 CU-10201临床试验结果近日发表</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科笛-B(02487)午后涨超30% CU-30101上市申请获受理 CU-10201临床试验结果近日发表\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-31 15:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1157895.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科笛-B(02487)午后涨超30%，截至发稿，涨30.26%，报10.16港元，成交额5270.85万港元。消息面上，科笛发布公告，集团的CU-30101药品上市许可申请获得中国国家药品监督管理局受理。据悉，CU-30101是一种用于皮肤表皮手术的局部利多卡因丁卡因复合表皮麻醉乳膏剂。此外，科笛公布，其治疗非结节性中度至重度寻常痤疮产品CU-10201(外用4%米诺环素泡沫剂...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1157895.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1157895.html","article_id":"2455607971","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20240731/20240731151225_54433.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2455607971","pubTimestamp":1722409892,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"科笛-B(02487)午后涨超30%，截至发稿，涨30.26%，报10.16港元，成交额5270.85万港元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03347":"泰格医药","BK1161":"生物科技","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1583":"高瓴概念","02487":"科笛-B"},"translate_title":"Hong Kong stock changes Kedi-B (02487) rose more than 30% in the afternoon, CU-30101 listing application was accepted, CU-10201 clinical trial results were recently released","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":1,"03347":1},"content_text":"智通财经APP获悉，科笛-B(02487)午后涨超30%，截至发稿，涨30.26%，报10.16港元，成交额5270.85万港元。消息面上，科笛发布公告，集团的CU-30101药品上市许可申请获得中国国家药品监督管理局受理。据悉，CU-30101是一种用于皮肤表皮手术的局部利多卡因丁卡因复合表皮麻醉乳膏剂。此外，科笛公布，其治疗非结节性中度至重度寻常痤疮产品CU-10201(外用4%米诺环素泡沫剂)的中国III期临床试验结果，于欧洲皮肤病与性病学会(EADV)的官方出版物《欧洲皮肤病与性病学杂志》(JEADV)线上发表。据悉，CU-10201是全球首个亦是唯一一个获批用于寻常痤疮治疗的外用米诺环素，也是首个获得国家药监局受理新药上市申请的外用米诺环素。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455607971"}